CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy

Johnson & Johnson said the EMA's Committee for Medicinal Products for Human Use recommended approval of an expanded TECVAYLI (teclistamab) indication for adults with relapsed or refractory multiple myeloma after at least one prior therapy. The positive CHMP opinion could broaden the eligible European patient population for the therapy, subject to final European Commission approval.

Analysis

The economic value is less about a near-term revenue step-up than preserving JNJ's myeloma treatment continuum as patients move earlier in the relapsed setting. TECVAYLI can defend JNJ against PFE's ELREXFIO and delay switching to non-JNJ regimens, but it also introduces internal sequencing tension with CARVYKTI (JNJ/LEGN): broader bispecific use may reduce the pool of BCMA-naive patients eligible for highest-value cellular therapy. Net franchise value is positive only if clinicians use TECVAYLI as a bridge or an alternative for patients unable to access CAR-T, rather than as a substitute for CARVYKTI.

The limiting variable over the next 1-3 months is not regulatory sentiment but country-level reimbursement, hospital capacity, and infection-management burden. Earlier-line use expands the addressable pool, yet continuous dosing, monitoring requirements, and treatment-related infection risk can make fixed-duration CAR-T economically attractive where manufacturing slots are available. Watch European label language, reimbursement decisions in Germany and France, and real-world discontinuation rates; those data will determine whether consensus revenue models need meaningful revision.

Contrarian view: the market may over-credit the label expansion before evidence of durable adoption. European hematologists are likely to reserve BCMA-directed therapy strategically because prior BCMA exposure can affect subsequent treatment sequencing, while PFE can compete aggressively on contracting. A sustained positive read-through for JNJ requires management to show that TECVAYLI growth is incremental to—not cannibalistic of—CARVYKTI demand and that gross-margin dilution from patient support and monitoring is contained over the next 2-4 quarters.

Key Decisions for Investors

• No standalone JNJ trade on the recommendation; the likely near-term earnings impact is too dependent on reimbursement timing and treatment sequencing. Reassess after JNJ's next two quarterly disclosures for European TECVAYLI growth, CARVYKTI demand, and explicit commentary on BCMA sequencing.
• Maintain a modest long JNJ / short PFE relative-value bias over 3-6 months only if European reimbursement begins converting rapidly. The thesis is that JNJ's integrated myeloma franchise has greater channel leverage; exit if PFE reports accelerating ELREXFIO uptake or JNJ signals CARVYKTI displacement rather than franchise expansion.
• Use LEGN as a monitoring hedge rather than a directional short: a material deceleration in CARVYKTI demand, longer manufacturing-slot availability, or commentary that earlier TECVAYLI use reduces CAR-T eligibility would be a negative read-through for LEGN and would falsify the JNJ-franchise-expansion thesis.
• Set an alert for EMA final authorization and the first major national reimbursement decision. Positive regulatory completion without reimbursement or utilization data is not a catalyst sufficient to underwrite multiple expansion; evidence of broad funded access is the actionable trigger.